Cargando…

Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia

BACKGROUND: The majority of acute myeloid leukaemia (AML) patients are over sixty years of age. With current treatment regimens, survival rates amongst these, and also those younger patients who relapse, remain dismal and novel therapies are urgently required. In particular, therapies that have anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khanim, Farhat L., Hayden, Rachel E., Birtwistle, Jane, Lodi, Alessia, Tiziani, Stefano, Davies, Nicholas J., Ride, Jon P., Viant, Mark R., Gunther, Ulrich L., Mountford, Joanne C., Schrewe, Heinrich, Green, Richard M., Murray, Jim A., Drayson, Mark T., Bunce, Chris M.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785482/ https://www.ncbi.nlm.nih.gov/pubmed/19997560 http://dx.doi.org/10.1371/journal.pone.0008147

Ejemplares similares

Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers
por: Murray, Jim, et al.
Publicado: (2019)

Metabolomic Profiling of Drug Responses in Acute Myeloid Leukaemia Cell Lines
por: Tiziani, Stefano, et al.
Publicado: (2009)

Correction: Metabolomic Profiling of Drug Responses in Acute Myeloid Leukaemia Cell Lines
por: Tiziani, Stefano, et al.
Publicado: (2009)

Hypoxia Triggers Major Metabolic Changes in AML Cells without Altering Indomethacin-Induced TCA Cycle Deregulation
por: Lodi, Alessia, et al.
Publicado: (2010)

Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells
por: Sheard, Jonathan J., et al.
Publicado: (2021)

Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active Disease
por: Lodi, Alessia, et al.
Publicado: (2013)

Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate
por: Khanim, F, et al.
Publicado: (2014)

Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies
por: Bunce, Chris M., et al.
Publicado: (2022)

Malonate as a ROS product is associated with pyruvate carboxylase activity in acute myeloid leukaemia cells
por: Reed, Michelle A. C., et al.
Publicado: (2016)

Tracer‐Based Metabolic NMR‐Based Flux Analysis in a Leukaemia Cell Line
por: Carrigan, John B., et al.
Publicado: (2016)

Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing
por: Jiang, Yao, et al.
Publicado: (2021)

Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate
por: Yuasa-Shibasaki, Erina, et al.
Publicado: (2017)

Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()
por: Nanda, Kavita, et al.
Publicado: (2016)

Analysis of the role of COP9 Signalosome (CSN) subunits in K562; the first link between CSN and autophagy
por: Pearce, Claire, et al.
Publicado: (2009)

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer*
por: Bloom, H. J. G.
Publicado: (1971)

Inhibitory Effects of Medroxyprogesterone Acetate on Mouse Endometrial Carcinogenesis
por: Niwa, Kenji, et al.
Publicado: (1995)

The Role of Autophagy and Apoptosis in the Combined Action of Plasma-Treated Saline, Doxorubicin, and Medroxyprogesterone Acetate on K562 Myeloid Leukaemia Cells
por: Pavlik, Tatyana, et al.
Publicado: (2023)

Correction: Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers
por: Veliça, Pedro, et al.
Publicado: (2010)

Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers
por: Veliça, Pedro, et al.
Publicado: (2009)

Effect of medroxyprogesterone acetate on the response of the rat mammary gland to carcinogenesis.
por: Russo, I. H., et al.
Publicado: (1989)

Incidence of Galactorrhea in Young Women Using Depot-Medroxyprogesterone Acetate
por: Omar, Hatim A., et al.
Publicado: (2006)

The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques
por: Daly, Michele B., et al.
Publicado: (2020)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma
por: Harmon, Quaker E., et al.
Publicado: (2022)

Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production
por: Khanim, F L, et al.
Publicado: (2011)

The potential for intramuscular depot medroxyprogesterone acetate as a self-bridging emergency contraceptive()
por: Schickler, Robyn, et al.
Publicado: (2020)

An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)()()
por: Katz, Micah, et al.
Publicado: (2020)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)

Changes in Hematologic Parameters during Treatment with Medroxyprogesterone Acetate for Breast Cancer
por: Yamamoto, Hitoshi, et al.
Publicado: (1991)

Metabolic plasticity in CLL: adaptation to the hypoxic niche
por: Koczula, K M, et al.
Publicado: (2016)

Bezafibrate for X-Linked Adrenoleukodystrophy
por: Engelen, Marc, et al.
Publicado: (2012)

Therapy of Canine Hyperlipidemia with Bezafibrate
por: De Marco, V., et al.
Publicado: (2017)

Uterine leiomyoma and its association with menstrual pattern and history of depo-medroxyprogesterone acetate injections
por: Amanti, L, et al.
Publicado: (2011)

Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review
por: Silva, P., et al.
Publicado: (2018)

A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia.
por: Downer, S., et al.
Publicado: (1993)

Phase II study of high-dose medroxyprogesterone acetate in advanced malignant melanoma.
por: Becher, R., et al.
Publicado: (1989)

Comparison of Sexual Dysfunction in Women Using Depo-Medroxyprogesterone Acetate (DMPA) and Cyclofem
por: Ozgoli, Giti, et al.
Publicado: (2015)

Colorectal tumor prevention by the progestin medroxyprogesterone acetate is critically dependent on postmenopausal status
por: Meijer, Bartolomeus J., et al.
Publicado: (2018)

Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach?
por: Malik, S. T., et al.
Publicado: (1991)

Effects of depot-medroxyprogesterone acetate on the immune microenvironment of the human cervix and endometrium: implications for HIV susceptibility
por: Smith-McCune, K K, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3ek4dhv2cqpjd4rihrr8rc6im2